FDA's NME Approval Rebound At Risk: Drought Of Novel Products In Line For Action In Remainder Of 2010 Could Depress Upward Trend From First Half
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Almost one-third fewer novel product applications are on FDA’s user fee calendar for the second half of 2010 as compared to the docket at the same point in 2009, a dearth that could imperil the slow but steady improvement in annual new molecular entity and novel biologic approvals after the nadirs reached earlier in the decade.
You may also be interested in...
FDA Expects Sharp Drop In Fee-Paying Drug Applications This Year
In what could be viewed as an ominous sign of declining pharmaceutical R&D productivity, FDA is predicting a sharp drop-off in fee-paying drug and biologic applications in the current fiscal year
FDA Expects Sharp Drop In Fee-Paying Drug Applications This Year
In what could be viewed as an ominous sign of declining pharmaceutical R&D productivity, FDA is predicting a sharp drop-off in fee-paying drug and biologic applications in the current fiscal year
FDA Expects Sharp Drop In Drug Applications This Year
Announcing the PDUFA fees for fiscal 2011, agency says it expects to receive 117.5 fee-paying full application equivalents in the current fiscal year, down 16 percent from the 2009 level.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: